Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - atazanavir sulfate 170.872mg (equiv 150 mg atazanavir) - capsule - 150 mg - active: atazanavir sulfate 170.872mg (equiv 150 mg atazanavir) excipient: crospovidone gelatin indigo carmine lactose monohydrate magnesium stearate titanium dioxide - atazanavir is indicated for the treatment of hiv-1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies.

Didžioji Britanija - anglų - MHRA (Medicines & Healthcare Products Regulatory Agency)

milpharm ltd - voriconazole - tablet - 50mg

Australija - anglų - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - phenytoin sodium, quantity: 250 mg - injection, solution - excipient ingredients: propylene glycol; water for injections; hydrochloric acid; sodium hydroxide; ethanol absolute - for the control of status epilepticus, tonic-clonic (grand mal), psychomotor seizures and the prevention of seizures occurring during or following neurosurgery. phenytoin will prevent or effectively decrease the incidence and severity of convulsive seizures in a high percentage of cases, with patients exhibiting little tendency to become resistant to its action. besides its effectiveness in controlling seizures, phenytoin frequently improves the mental condition and outlook of epileptic patients. it has also been used in the treatment of certain cardiac arrhythmias, particularly in those patients who do not respond to conventional antiarrhythmic agents or to cardioversion. phenytoin serum level determinations may be necessary for optimal dosage adjustments (see dosage and administration)

Australija - anglų - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - phenytoin, quantity: 50 mg - tablet, chewable - excipient ingredients: quinoline yellow; saccharin sodium; magnesium stearate; purified talc; sunset yellow fcf; flavour; maize starch; sucrose - dilantin is indicated for the control of grand mal and psychomotor seizures. dilantin will prevent or effectively decrease the incidence and severity of convulsive seizures in a high percentage of cases, with patients exhibiting little tendency to become resistant to its action. besides its effectiveness in controlling seizures, dilantin frequently improves the mental condition and outlook of epileptic patients and there is also increasing evidence that dilantin is valuable in the prevention of seizures occurring during or after neurosurgery. phenytoin serum level determinations may be necessary for optimal dosage adjustments (see dosage and administration).

Australija - anglų - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - rilpivirine hydrochloride, quantity: 27.5 mg (equivalent: rilpivirine, qty 25 mg); dolutegravir, quantity: 50 mg - tablet, film coated - excipient ingredients: macrogol 3350; silicified microcrystalline cellulose; povidone; sodium starch glycollate type a; polyvinyl alcohol; microcrystalline cellulose; magnesium stearate; lactose monohydrate; iron oxide yellow; croscarmellose sodium; iron oxide red; mannitol; purified talc; titanium dioxide; sodium stearylfumarate; polysorbate 20 - juluca (dolutegravir/rilpivirine) is indicated for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adults who are virologically-suppressed (hiv-1 rna less than 50 copies per ml) on a stable antiretroviral regimen for at least 6 months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor (see section 5.1 pharmacodynamic properties, clinical trials).

Airija - anglų - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - phenytoin sodium - solution for injection/infusion - 250 mg/5ml - hydantoin derivatives; phenytoin

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

state of florida doh central pharmacy - fosamprenavir calcium (unii: id1gu2627n) (amprenavir - unii:5s0w860xnr) - lexiva® is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv-1) infection. the following points should be considered when initiating therapy with lexiva plus ritonavir in protease inhibitor-experienced patients: lexiva is contraindicated: drug class/drug name clinical comment alpha 1-adrenoreceptor antagonist: alfuzosin potentially increased alfuzosin concentrations can result in hypotension. antiarrhythmics: flecainide, propafenone potential for serious and/or life-threatening reactions such as cardiac arrhythmias secondary to increases in plasma concentrations of antiarrhythmics if lexiva is co-prescribed with ritonavir . antimycobacterials: rifampina may lead to loss of virologic response and possible resistance to lexiva or to the class of protease inhibitors. ergot derivatives: dihydroergotamine, ergonovine, ergotamine, methylergonovine potential for serious and/or life-threatening reactions such as acute ergot toxicity characterized by pe

Australija - anglų - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - lamivudine, quantity: 300 mg; dolutegravir sodium, quantity: 52.6 mg (equivalent: dolutegravir, qty 50 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate type a; povidone; mannitol; titanium dioxide; microcrystalline cellulose; sodium stearylfumarate; magnesium stearate; hypromellose; macrogol 400 - dovato (a fixed dose combination of dolutegravir and lamivudine) is indicated for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adults and adolescents (from 12 years of age weighing at least 40kg): ? in antiretroviral treatment-na?ve patients with no antiretroviral treatment history who have no known or suspected resistance to either antiretroviral component; or ? to replace the current antiretroviral regimen in those who are virologically suppressed (hiv-1 rna less than 50 copies per ml) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to the integrase inhibitor class or lamivudine (see section 5.1 pharmacodynamic properties, clinical trials).

Malta - anglų - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - lopinavir, ritonavir - film-coated tablet - lopinavir 200 mg ritonavir 50 mg - antivirals for systemic use

Airija - anglų - HPRA (Health Products Regulatory Authority)

upjohn eesv - phenytoin sodium - solution for injection/infusion - 250 mg/5ml - hydantoin derivatives; phenytoin